BioAtla, Inc. (OTCPK: BCAB)
Health Care · Biotechnology · US
$1.35
-24.78% today · -97.8% 1Y
BioAtla, Inc. (OTCPK: BCAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.26M and employs 41 people.
Over the last twelve months the share price has lost 97.8%, trading between 1.07 and 71.50.
Tweenvest scores BioAtla, Inc. across four factors: quality 10/100, value 63/100. Its strongest factor is value.
BCAB price history
Key figures
- Market cap
- $2.26M
- Revenue (TTM)
- $8.75M
- P/E
- -0.07
- EPS
- -16.88
- Dividend yield
- —
- Beta (5Y)
- 0.50
- 52-week high
- $71.50
- 52-week low
- $1.07
- Avg volume (3M)
- —
- Shares outstanding
- 1.67M
- Employees
- 41
- Next earnings
- —
About BioAtla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
- ISIN
- US09077B2034
- Founded
- 2007
- Listed since
- Dec 16, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ValiRx plcAIM: VAL | $2.44M | £0.00 | -9.68% |
| Quest PharmaTech Inc.TSXV: QPT | $2.37M | CA$0.02 | 0.00% |
| ExpreS2ion Biotech Holding AB (publ)OM: EXPRS2 | $2.34M | Skr0.99 | +3.13% |
| BSF Enterprise PlcLSE: BSFA | $2.28M | £0.01 | -10.00% |
| Predilife S.A.ENXTPA: ALPRE | $2.25M | €0.52 | -10.65% |
| Vectus Biosystems LimitedASX: VBS | $2.23M | AU$0.05 | +6.00% |
| Cynata Therapeutics LimitedASX: CYP | $2.15M | AU$0.01 | 0.00% |
| Transgene Biotek LimitedBSE: 526139 | $2.12M | Rs2.64 | +3.53% |